본문으로 건너뛰기
← 뒤로

[Corrigendum] Src homology phosphotyrosyl phosphatase 2 mediates cisplatin‑related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells.

Oncology reports 2026 Vol.55(1)

Yin Y, Tang L, Shi L

📝 환자 설명용 한 줄

Following the publication of this paper, and the publication of an Expression of Concern statement (doi.org/10.3892/or.2025.8979), the authors have replied concerning an issue that was drawn to our at

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Yin Y, Tang L, Shi L (2026). [Corrigendum] Src homology phosphotyrosyl phosphatase 2 mediates cisplatin‑related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells.. Oncology reports, 55(1). https://doi.org/10.3892/or.2025.9026
MLA Yin Y, et al.. "[Corrigendum] Src homology phosphotyrosyl phosphatase 2 mediates cisplatin‑related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells.." Oncology reports, vol. 55, no. 1, 2026.
PMID 41268600

Abstract

Following the publication of this paper, and the publication of an Expression of Concern statement (doi.org/10.3892/or.2025.8979), the authors have replied concerning an issue that was drawn to our attention by an interested reader; namely, that the immunohistochemical images shown in Figs. 1E and 5E appeared to show an overlapping section, even though Figs. 1 and 5 were intended to show the results of SHP2 and Ras expression experiments, respectively. The authors were able to check their data, and realized that Fig. 5 had inadvertently been assembled incorrectly. The revised version of Fig. 5, now showing the correct data for Fig. 5E, is shown below. Note that these errors did not adversely affect either the results or the overall conclusions reported in this study. All the authors agree with the publication of this corrigendum, and are grateful to the Editor of for allowing them the opportunity to publish this. They also wish to apologize to the readership of the Journal for any inconvenience caused. [Oncology  Reports 39: 611‑618, 2018; DOI: 10.3892/or.2017.6109.

같은 제1저자의 인용 많은 논문 (5)